Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-667 pembrolizumab plus chemotherapy in children and young adults with slow early response classical Hodgkin lymphoma
2017-001123-53Phase 2
- Sponsor
- Merck & Co.
- Start
- Jun 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in classical Hodgkin lymphoma (cHL) (2 arms), sponsored by Merck & Co. Primary endpoint: Objective response rate.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2017-001123-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001123-53.